221 625

Cited 0 times in

15-hydroxyprostaglandin dehydrogenase is associated with the troglitazone-induced promotion of adipocyte differentiation in human bone marrow mesenchymal stem cells.

Noh, M; Lee, SH
Biomolecules & therapeutics, 18(1):16-23, 2010
Journal Title
Biomolecules & therapeutics
Adipocyte differentiation in human bone marrow mesenchymal stem cells (hBM-MSCs) is not as efficient as that in murine pre-adipocytes when induced by adipogenic agents including insulin, dexamethasone, and 3-isobutyl-1- methylxanthine (IDX condition). Therefore, the promotion of adipocyte differentiation in hBM-MSCs has been used as a cell culture model to evaluate insulin sensitivity for anti-diabetic drugs. In hBM-MSCs, PPARγ agonists or sulfonylurea anti-diabetic drugs have been added to IDX conditions to promote adipocyte differentiation. Here we show that troglitazone, a peroxisome proliferator-activated receptor-gamma (PPARγ) agonist, significantly reduced the levels of anti-adipogenic PGE2 in IDX-conditioned hBM-MSC culture supernatants when compared to PGE2 levels in the absence of PPARγ agonist. However, there was no difference in the mRNA levels of cyclooxygenases (COXs) and the activities of COXs and prostaglandin synthases during adipocyte differentiation in hBM-MSCs with or without troglitazone. In hBM-MSCs, troglitazone significantly increased the mRNA level of 15-hydroxyprostaglandin dehydrogenase (HPGD) which can act to decrease PGE 2 levels in culture. These results suggest that the role of PPARγ activation in promoting adipocyte differentiation in hBM-MSCs is to reduce anti-adipogenic PGE2 levels through the up-regulation of HPGD expression.
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Physiology
AJOU Authors
이, 수환
Files in This Item:
Full-Text Not Available.txtDownload
RIS (EndNote)
XLS (Excel)


해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.